Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination studies with leuprolide.

E D Crawford1

  • 1University of Colorado Health Science Center, Division of Urology, Denver.

European Urology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Combination therapy with leuprolide and flutamide significantly improves survival and delays progression in advanced prostate cancer patients. This approach, combining medical castration with antiandrogens, offers therapeutic advantages.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating central nervous system metagenomics and host response for diagnosis of tuberculosis meningitis and its mimics.

Nature communications·2022
Same author

Corroborating evidence refutes batch effect as explanation for fetal bacteria.

Microbiome·2021
Same author

Viable bacterial colonization is highly limited in the human intestine in utero.

Nature medicine·2020
Same author

Acute West Nile Virus Meningoencephalitis Diagnosed Via Metagenomic Deep Sequencing of Cerebrospinal Fluid in a Renal Transplant Patient.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 to remove unwanted high-abundance species in sequencing libraries and molecular counting applications.

Genome biology·2016
Same author

Genetic variation in the vitamin d pathway in relation to risk of prostate cancer--results from the breast and prostate cancer cohort consortium.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2013
Same journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
See all related articles

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Advanced prostate cancer requires effective treatment strategies.
  • Hormonal therapies aim to reduce androgen levels.
  • LHRH analogs and antiandrogens are key hormonal agents.

Purpose of the Study:

  • To evaluate the efficacy of leuprolide (LHRH analog) monotherapy versus combination therapy with flutamide (antiandrogen) in advanced prostate cancer.
  • To compare survival time and time to disease progression between treatment groups.

Main Methods:

  • Double-blind, multicenter clinical trial.
  • Involved 603 patients with advanced prostate cancer.
  • Compared leuprolide alone versus leuprolide plus flutamide.

Related Experiment Videos

Main Results:

  • Combination therapy showed significantly longer median survival (35 vs. 27.9 months) and time to progression (16.9 vs. 13.9 months).
  • Benefits were most pronounced in patients with minimal disease and good performance status.
  • Black patients had a shorter survival time compared to white patients.
  • Both treatments were well-tolerated.

Conclusions:

  • Combining LHRH analogs with antiandrogens offers therapeutic advantages in advanced prostate cancer.
  • This combination effectively suppresses androgen actions, including those from adrenal sources.
  • Further research into specific patient subgroups and racial differences in survival is warranted.